Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rabbit Polyclonal to Human IKBKB / IKK2 / IKK Beta
Rabbit Polyclonal (IgG) to Human IKBKB / IKK2 / IKK Beta
Human, Mouse, Rat
Western blot, Immunoprecipitation, ELISA
Human IKBKB / IKK2 / IKK Beta
Human, Mouse, Rat (tested or 100% immunogen sequence identity)
Delipidated and defibrinated
Western blot (1:500 - 1:1000)
ELISA (1:1000 - 1:5000)
Specificity and Use
IKBKB / IKK2 / IKK Beta antibody was raised against ikB beta peptide corresponding to a region near the C-terminus of the human protein conjugated to KLH. AA Sequence: RQP PSP ASK PLP DDP NPA.
Recognizes 45kD human IkBb. May react non-specifically with other proteins. Species cross-reactivity: mouse and rat.
Suitable for Immunoprecipitation, Western Blot, ELISA. ELISA: 1:1000-1:5000. Western Blot: 1:500-1:1000 (Peroxidase conjugated goat anti-rabbit IgG (H&L). Anti-IkB beta is suitable for the detection by immunoblot of human, mouse and rat IkB beta.
PBS, pH 7.2, 0.01% sodium azide.
Long term: Add glycerol (40-50%) -20°C; Short term: +4°C
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome.